anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Cariprazine
Trial phase: Phase 2
ATC code: N05AX15
SMILES: CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(c3cccc(Cl)c3Cl)CC2)CC1
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 93
Group description: Participants received cariprazine 1.5 mg capsule once, twice or three times a day depending on their response and tolerability
Eligibility criteria:
Inclusion Criteria:

Patients who have completed the double-blind treatment period of the lead-in study RGH-MD-16 (NCT 00694707)
Patients who have responded to double-blind treatment in the lead-in study as defined as ≥ 20% reduction relative to Visit 2 (Baseline) of the Positive and Negative Syndrome Scale (PANSS) total score and a Clinical Global Impressions-Severity (CGI-S) score of ≤ 3.
Patients eligible to continue as outpatients based on the opinion of the Principal Investigator.
Patients must have a caregiver to ensure treatment compliance.

Exclusion Criteria:

Patients with clinically significant abnormalities on physical examination, laboratory, vital signs, and/or electrocardiogram (ECG).
Intervention: PRAMLINTIDE
Trial phase: Not Applicable
ATC code: A10BX05
SMILES: [H]N[C@@H](CCCCN)C(=O)N[C@H]1CSSC[C@@H](C(=O)N[C@@H](C)C(=O)N[C@]([H])(C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](Cc2cnc[nH]2)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc2ccccc2)C(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@]([H])(C(=O)N[C@@H](CC(C)C)C(=O)N2CCC[C@H]2C(=O)N2CCC[C@H]2C(=O)N[C@]([H])(C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@]([H])(C(=O)N[C@@H](Cc2ccc(O)cc2)C(N)=O)[C@@H](C)O)C(C)C)[C@@H](C)O)[C@@H](C)CC)C(C)C)[C@@H](C)O)NC(=O)[C@]([H])([C@@H](C)O)NC(=O)[C@H](C)NC(=O)[C@]([H])([C@@H](C)O)NC(=O)[C@H](CC(N)=O)NC1=O
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 10
Group description: Subcutaneous injection of pramlintide prior to each meal with reduction of mealtime bolus insulin
Eligibility criteria:
Inclusion Criteria:

Between 13 and 17 years of age, inclusive
Diagnosed with type 1 diabetes for > 1 year
Hemoglobin A1c between 7.5 and 10% inclusive
Currently using carbohydrate to insulin ratio
Acceptable form of birth control

Exclusion Criteria:

Use of oral hyperglycemic agents or medications affecting blood sugar levels
Recurrent severe hypoglycemia requiring assistance in past 6 months
History of hypoglycemia unawareness
History of gastroparesis requiring use of drugs that stimulate gastrointestinal motility
Previous use of pramlintide
Intervention: Zoledronic acid
Trial phase: Phase 2
ATC code: M05BA08 | M05BB08
SMILES: O=P(O)(O)C(O)(Cn1ccnc1)P(=O)(O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 8
Group description: zoledronic acid: zoledronic acid, 5mg, iv
Eligibility criteria:
Inclusion Criteria:

Men and women
Age 18 years and older
Spinal cord injury within 8 weeks of study entry
ASIA AIS A or B
Medically stable in the opinion of their physiatrist
Able to have dexa performed
Able to return for follow-up at 6 and 12 months

Exclusion Criteria:

Vitamin D deficiency
Hypocalcemia
Renal insufficiency (estimated creatinine clearance <30ml/min)
Abnormal thyroid hormone status
Abnormal mental status
Osteoporosis at the hip or spine by dexa
Intervention: Acyclovir Sodium
Trial phase: Phase 3
SMILES: Nc1nc([O-])c2ncn(COCCO)c2n1.[Na+]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 56
Group description: Patients receive weight-based IV acyclovir sodium every 8 or 12 hours.
Eligibility criteria:
Inclusion Criteria:

Be 18 years of age or older.
Receiving treatment in inpatient oncology services at Wake Forest University Baptist Medical Center
Receiving chemotherapy or have received chemotherapy within the past 2 weeks
Seropositive herpes simplex virus (HSV)-1 or HSV-2 immunoglobulin antibody assay
Creatinine clearance ≥ 50 mL/min
Intravenous acyclovir sodium therapy is deemed necessary by the physician based upon clinical judgement (i.e., mucositis, vomiting, decreased GI absorption)

Exclusion Criteria:

Pregnant or nursing
Hypersensitivity to acyclovir sodium
High tumor burden (i.e., WBC > 50,000/mm^3 at admission)
Neutropenic, defined as one of the following:
ANC < 500/mm^3
ANC < 1,000/mm^3 with a predicted decrease to 500/mm^3
Active HSV infection, as evidenced by any of the following:
Positive HSV cultures
Oral lesions
Receiving 5 mg/kg acyclovir sodium every 8 hours
Intervention: Acyclovir Sodium
Trial phase: Phase 3
SMILES: Nc1nc([O-])c2ncn(COCCO)c2n1.[Na+]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 55
Group description: Patients receive low-dose IV acyclovir sodium every 8 or 12 hours.
Eligibility criteria:
Inclusion Criteria:

Be 18 years of age or older.
Receiving treatment in inpatient oncology services at Wake Forest University Baptist Medical Center
Receiving chemotherapy or have received chemotherapy within the past 2 weeks
Seropositive herpes simplex virus (HSV)-1 or HSV-2 immunoglobulin antibody assay
Creatinine clearance ≥ 50 mL/min
Intravenous acyclovir sodium therapy is deemed necessary by the physician based upon clinical judgement (i.e., mucositis, vomiting, decreased GI absorption)

Exclusion Criteria:

Pregnant or nursing
Hypersensitivity to acyclovir sodium
High tumor burden (i.e., WBC > 50,000/mm^3 at admission)
Neutropenic, defined as one of the following:
ANC < 500/mm^3
ANC < 1,000/mm^3 with a predicted decrease to 500/mm^3
Active HSV infection, as evidenced by any of the following:
Positive HSV cultures
Oral lesions
Receiving 5 mg/kg acyclovir sodium every 8 hours
Intervention: Ursodeoxycholic acid
Trial phase: Not Applicable
ATC code: A05AA02
SMILES: [H][C@@]12C[C@H](O)CC[C@]1(C)[C@@]1([H])CC[C@@]3(C)[C@@]([H])(CC[C@]3([H])[C@H](C)CCC(=O)O)[C@]1([H])[C@@H](O)C2
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 42
Group description: Esophageal biopsy: After the esophageal perfusions described above, 12 biopsy specimens of the squamous epithelium will be taken at a level 2 cm proximal to the squamocolumnar junction at baseline (6 biopsies will be used to establish primary cell cultures and six will be used for molecular analyses); 6 more biopsy specimens will be taken at the same level immediately after bile acid perfusion for molecular analyses. In patients with Barrett's esophagus, 12 biopsy specimens of the specialized intestinal metaplasia also will be taken at a level 1 cm distal to the squamocolumnar junction at baseline (6 biopsies will be used to establish primary cell cultures and six will be used for molecular analyses); 6 more biopsy specimens will be taken at the same level immediately after bile acid perfusion for molecular analyses.
Eligibility criteria:
Inclusion Criteria:

Patients who have been scheduled for elective endoscopic examination at the Dallas VA Medical Center for the evaluation of GERD or Barrett's esophagus

Exclusion Criteria:

Patients unwilling or unable to provide informed consent
Patients with esophageal carcinomas
Patients with esophageal varices
Patients taking warfarin or clopidogrel
Coagulopathy that precludes safe biopsy of the esophagus
Comorbidity that precludes safe participation in the study
Allergy to omeprazole or UDCA
Pregnancy
Intervention: Cycloserine
Trial phase: Phase 2
ATC code: J04AB01
SMILES: N[C@@H]1CONC1=O
Sex: All
Age groups: Child
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 30
Group description: Involves receiving cognitive-behavioral treatment of OCD symptoms for 10 sessions. One hour prior to sessions 4-10, the child will take either 1 or 2 pills containing 25mg of D-cycloserine. The number of pills depends on the child's weight (e.g., about 46kgs takes 2 capsules).
Eligibility criteria:
Inclusion Criteria:

The child must receive a principal diagnosis of OCD at Baseline, based on DSM-IV criteria. This diagnosis will be derived from the Anxiety Disorder Interview Schedule for DSM-IV-Child Interview Schedule - Parent version (ADIS-IV-P), and must reflect a clinical severity rating of 4 or above
CY-BOCS Total Score ≥ 16
Be between the ages of 8 and 17 years
Score ≥ 80 on the Peabody Picture Vocabulary Test-3rd Edition (Dunn & Dunn, 1997)
At least one parent available to accompany the child to all sessions;
English speaking.

Exclusion Criteria:

Psychosis, pervasive developmental disorder, bipolar disorder, or current suicidal intent measured by the ADIS-IV-P and all available clinical information
Principal diagnosis other than OCD
Youth with mental rituals, incompleteness, or hoarding symptoms as E/RP exercises would be more difficult to conduct/monitor than those with overt rituals
Unavailability of at least one caregiver to participate in the treatment
Refusal of parent to accept random assignment to treatment condition
A positive diagnosis in the caregiver of mental retardation, psychosis, clinically significant tics, or other psychiatric disorders or conditions that would limit their ability to understand E/RP (based on clinical interview)
Weight less than 25.0 kg or greater than 80.0kg
Epilepsy, renal insufficiency, and current or past history of alcohol abuse (DCS is contraindicated for such conditions)
Pregnant or having unprotected sex [in females] as the effects of DCS on pregnant youth are unknown
General poor physical health as determined by medical physical and laboratory tests.
Intervention: Lurasidone
Trial phase: Phase 3
ATC code: N05AE05
SMILES: [H][C@@]12C(=O)N(C[C@@H]3CCCC[C@H]3CN3CCN(c4nsc5ccccc45)CC3)C(=O)[C@]1([H])[C@H]1CC[C@@H]2C1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 183
Group description: lurasidone + (lithium or divalproex) : lurasidone 20 mg/day for Days 1-2-3, 40 mg/day for Days 4-5-6, and 60 mg/day on Day 7.
Eligibility criteria:
Inclusion Criteria:

Subject is diagnosed with bipolar I disorder, most resent episode depressed
Subject must have a lifetime history of at least one bipolar manic or mixed episode
Subject must be taking lithium or divalproex at least 28 days prior to screening

Exclusion Criteria:

History of nonresponse to an adequate (6-week) trial of three or more antidepressants (with or without mood stabilizers) during the current episode
Subject has been hospitalized for a manic or mixed episode within 60 days prior to randomization
Imminent risk of suicide or injury to self, others, or property
Intervention: Lurasidone
Trial phase: Phase 3
ATC code: N05AE05
SMILES: [H][C@@]12C(=O)N(C[C@@H]3CCCC[C@H]3CN3CCN(c4nsc5ccccc45)CC3)C(=O)[C@]1([H])[C@H]1CC[C@@H]2C1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 167
Group description: lurasidone : lurasidone 20 mg/day for Days 1-2, 40 mg/day for Days 3-4, 60 mg/day for Days 5-6 and 80 mg/day on Day 7 and 80-120 mg/day
Eligibility criteria:
Inclusion Criteria:

Subject is diagnosed with bipolar I disorder, most resent episode depressed
Subject must have a lifetime history of at least one bipolar manic or mixed episode

Exclusion Criteria:

History of nonresponse to an adequate (6-week) trial of three or more antidepressants (with or without mood stabilizers) during the current episode
Subject has been hospitalized for a manic or mixed episode within 60 days prior to randomization
Imminent risk of suicide or injury to self, others, or property
Intervention: Lurasidone
Trial phase: Phase 3
ATC code: N05AE05
SMILES: [H][C@@]12C(=O)N(C[C@@H]3CCCC[C@H]3CN3CCN(c4nsc5ccccc45)CC3)C(=O)[C@]1([H])[C@H]1CC[C@@H]2C1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 164
Group description: lurasidone : lurasidone 20 mg/day for Days 1-7, beginning day 8 flexibly dosed 20-60 mg/day
Eligibility criteria:
Inclusion Criteria:

Subject is diagnosed with bipolar I disorder, most resent episode depressed
Subject must have a lifetime history of at least one bipolar manic or mixed episode

Exclusion Criteria:

History of nonresponse to an adequate (6-week) trial of three or more antidepressants (with or without mood stabilizers) during the current episode
Subject has been hospitalized for a manic or mixed episode within 60 days prior to randomization
Imminent risk of suicide or injury to self, others, or property
Intervention: Lurasidone
Trial phase: Phase 3
ATC code: N05AE05
SMILES: [H][C@@]12C(=O)N(C[C@@H]3CCCC[C@H]3CN3CCN(c4nsc5ccccc45)CC3)C(=O)[C@]1([H])[C@H]1CC[C@@H]2C1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 813
Group description: lurasidone: Lurasidone 20-120 mg/d Flexibly Dosed - 24 weeks
Eligibility criteria:
Inclusion Criteria:

Subject is judged by the investigator to be suitable for participation in a 24-week clinical trial involving open-label lurasidone treatment
Subject has completed the 6-week treatment period and all required assessments on the final study visit (Day 42, Visit 8) of either Study D1050235, NCT#00868452 or Study D1050236, NCT#008668699.

Exclusion Criteria:

Imminent risk of suicide, injury to self or to others, or damage to property
Subject has evidence of severe movement disorders.
Subject tests positive for drugs of abuse (at Visit 8 in Study D1050235, NCT#00868452 or D1050236, NCT#008688699).
Intervention: Regadenoson
Trial phase: Phase 4
ATC code: C01EB21
SMILES: CNC(=O)c1cnn(-c2nc(N)c3ncn([C@@H]4O[C@H](CO)[C@@H](O)[C@H]4O)c3n2)c1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 20
Group description: Twenty healthy subjects underwent CMR perfusion imaging during resting conditions, during regadenoson-induced hyperemia (0.4 mg), and after 15 min of recovery.
Eligibility criteria:
Inclusion Criteria:

Suspected coronary artery disease
Symptoms of possible coronary artery disease

Exclusion Criteria:

Acute ST-elevation myocardial infarction
Second or third degree AV block
Severe Renal Disease (Glomerular Filtration Rate (GFR) <30cc/min or hemodialysis)
Contra-indications to MRI (i.e. Implantable Cardioverter Defibrillator (ICD), pacemaker, aneurysm clip, etc)
Hemodynamic instability
Inability to provide informed consent
Severe claustrophobia
Pregnancy
Age <18 years
Intervention: Dexmedetomidine
Trial phase: Phase 2
ATC code: N05CM18
SMILES: Cc1cccc([C@H](C)c2c[nH]cn2)c1C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 36
Group description: Dexmedetomidine: Dexmedetomidine will be started at a rate of 0.2mcg/kg/hr and titrated by 0.1 mcg/kg/hr every 30 minutes to a maximum of 0.7 mcg/kg/hr to maintain a Riker-SAS 3-4.
Eligibility criteria:
Inclusion Criteria:

Age ≥ 18 years
Acute respiratory failure requiring the initiation of NPPV
Admission to the medical ICU service at Tufts Medical Center or Winchester Hospital

Exclusion Criteria:

Patients with delirium (intensive care delirium screening checklist score ≥ 4) or disorientation (not oriented to person or place)
Receiving NPPV for ≥ 8 hours (includes treatment with NPPV at an outside hospital)
Intubation and mechanical ventilation in the past month based on hospital admission note
Age ≥ 85 years
Inability of the potential subject to give informed consent
Current treatment with antipsychotic agent based on hospital admission note
Heart rate ≤ 50 bpm
Systolic blood pressure ≤ 90 mmHg
History of heart block without pacemaker use or severe ventricular dysfunction (EF ≤25%) based on hospital admission note
Acute alcohol withdrawal based on hospital admission note
History of end stage liver failure (based on presence of ≥ 1 or more of the following: AST/ALT ≥ 2 times ULN, INR ≥ 2, total bilirubin ≥ 1.5
Irreversible brain disease consistent with severe dementia based on hospital admission note
Pregnancy (all women of child-bearing age will undergo a pregnancy test prior to study enrollment)
Treatment with clonidine or dexmedetomidine in the past 30 days based on hospital admission note
Known allergy or sensitivity to clonidine or dexmedetomidine
Intervention: Lisinopril
Trial phase: Phase 2
ATC code: C09AA03 | C09BA03 | C09BB03 | C10BX07
SMILES: NCCCC[C@H](N[C@@H](CCc1ccccc1)C(=O)O)C(=O)N1CCC[C@H]1C(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 8
Group description: ace inhibitor

lisinopril: 1 x 40 mg per day
Eligibility criteria:
Inclusion Criteria:

Age > 60 years
BP 120/80 or higher *(bps will be checked weekly first 4 weeks to ensure < 130/80 - IF bp remains > 130/80 we will administer other bp meds per JNC VII guidelines)
CKD stage 3 (GFR 30 - 59 ml/min) for CKD group; no CKD for control group

Exclusion Criteria:

Known significant CVD (history of Myocardial infarction (MI), recurrent stroke, or New York Heart Association (NYHA) class III or greater).
Serum potassium > 5.2 meq/L
Known allergy or hypersensitivity to ACE inhibitor or ARB
Female of childbearing age not practicing contraception
Current treatment with an Angiotensin Converting Enzyme Inhibitors (ACE-I) or Angiotensin-Receptor Blockers (ARB) (Note: can participate if on ACE-I after 6 week washout period)
History of ACE-I induced angioedema
History of angioedema, hereditary or idiopathic

Persons lacking consent capacity

500 mg/dL proteinuria on 2 consecutive spot urine protein/creat ratios
Intervention: Lisinopril
Trial phase: Phase 2
ATC code: C09AA03 | C09BA03 | C09BB03 | C10BX07
SMILES: NCCCC[C@H](N[C@@H](CCc1ccccc1)C(=O)O)C(=O)N1CCC[C@H]1C(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 17
Group description: ace-inhibitor

lisinopril: 1 x 40 mg per day
Eligibility criteria:
Inclusion Criteria:

Age > 60 years
BP 120/80 or higher *(bps will be checked weekly first 4 weeks to ensure < 130/80 - IF bp remains > 130/80 we will administer other bp meds per JNC VII guidelines)
CKD stage 3 (GFR 30 - 59 ml/min) for CKD group; no CKD for control group

Exclusion Criteria:

Known significant CVD (history of Myocardial infarction (MI), recurrent stroke, or New York Heart Association (NYHA) class III or greater).
Serum potassium > 5.2 meq/L
Known allergy or hypersensitivity to ACE inhibitor or ARB
Female of childbearing age not practicing contraception
Current treatment with an Angiotensin Converting Enzyme Inhibitors (ACE-I) or Angiotensin-Receptor Blockers (ARB) (Note: can participate if on ACE-I after 6 week washout period)
History of ACE-I induced angioedema
History of angioedema, hereditary or idiopathic

Persons lacking consent capacity

500 mg/dL proteinuria on 2 consecutive spot urine protein/creat ratios
Intervention: Cycloserine
Trial phase: Not Applicable
ATC code: J04AB01
SMILES: N[C@@H]1CONC1=O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 41
Group description: DCS: 1. Cognitive behavioral treatment with exposure therapy plus D-Cycloserine (100 mg on days of therapy session (approximately 9 times)
Eligibility criteria:
Inclusion Criteria:

English-speaking adults
Age 18-70
Survivor of a variety of traumas (e.g., motor vehicle and accidents, burns and others injuries, combat, World Trade Center attack, etc.)
Diagnosed with PTSD
In good health. For persons with chronic injuries/conditions related to their accidents, "good health" is defined as the injury being in a state of stabilization and able to attend weekly outpatient sessions.

Exclusion Criteria:

Current organic mental disorder
Schizophrenia or symptoms of psychosis/delusions
Bipolar disorder
Current substance abuse or dependence
Active suicidal/homicidal ideation, intent, or plan
Use of pacemaker
Significant health impairment, including renal disease
Taking oral anticoagulant medication, ethionamide (Trecator-SC), isoniazid (INH), or anti-depressant medication
Hypersensitivity to cycloserine
History of seizures
Pregnant or currently trying to conceive, or breastfeeding
Intervention: Minoxidil
Trial phase: Phase 2
ATC code: C02DC01 | D11AX01
SMILES: Nc1cc(N2CCCCC2)nc(N)[n+]1[O-]
Sex: All
Age groups: Child | Adult
Healthy volunteers: No
Participants at risk: 9
Group description: Normotension: 0.2mg/kg/day for children under 12 and 5mg/day for children aged 12 or more.

Hypertension: 0.2mg/kg/day, increasing up to a maximal dosage of 1 mg/kg) for children under 12. 5mg/day, increasing as needed of 0.1 mg/kg/day (up to a maximal dosage of 40 mg/day) for children aged 12 or more.

Minoxidil: Normotension: 0.2mg/kg/day for children under 12 and 5mg/day for children aged 12 or more.

Hypertension: 0.2mg/kg/day, increasing up to a maximal dosage of 1 mg/kg) for children under 12. 5mg/day, increasing as needed of 0.1 mg/kg/day (up to a maximal dosage of 40 mg/day) for children aged 12 or more.
Eligibility criteria:
Inclusion Criteria:

proven diagnosis of Williams Beuren syndrome (genetic test)
normotension or hypertension, treated or not
male or female,
6< age <18,
negative pregnancy test for childbearing potential female
effective birth control for sexually active female
signed consent form collected from parents or legal guardian

Exclusion Criteria:

pulmonary hypertension secondary to mitral stenosis
myocardial infarction within 1 month prior randomization
known allergies to minoxidil or any of the components of Lonoten.
asthma
renal failure (creatinine clearance <40ml/min)
no affiliation to a national health insurance program (social security)
intolerance to lactose
current vasodilator anti hypertensive treatment
Intervention: Sultamicillin
Trial phase: Phase 2 | Phase 3
ATC code: J01CR04 | J01CR50
SMILES: [H][C@]12SC(C)(C)[C@H](C(=O)OCOC(=O)[C@@H]3N4C(=O)C[C@@]4([H])S(=O)(=O)C3(C)C)N1C(=O)[C@H]2NC(=O)[C@H](N)c1ccccc1
Sex: Female
Age groups: Adult
Healthy volunteers: No
Participants at risk: 43
Group description: Unasyn: Unasyn 3 grams intravenously every 6 hours, plus intravenous normal saline placebo dose every 8 hours until 24 hours post delivery.
Eligibility criteria:
Inclusion Criteria:

Pregnant women in labor or undergoing induction of labor
Greater than or equal to 18 years of age
Diagnosed with chorioamnionitis as defined by maternal temperature > or = 38.0 degrees Centigrade plus at least one of the following: maternal tachycardia (heart rate >110), fetal tachycardia (fetal heart rate baseline >160), purulent amniotic fluid, uterine tenderness.

Exclusion Criteria:

Allergy or adverse reaction to penicillin or ampicillin, gentamicin, or sulbactam
Having received antibiotics for the treatment of preterm premature rupture of membranes or other condition within the last 7 days
Acute or chronic renal disease or insufficiency (creatinine >1.0)
Hearing loss
Major fetal congenital anomalies or intrauterine fetal demise
Neutropenia
HIV
Myasthenia gravis or other neuromuscular disorder
Intervention: MK-1496
Trial phase: Phase 1
SMILES: C[C@H](N)c1ccc([C@H](O)CNC(C)(C)C)cc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 3
Group description: Participants receiving MK-1496 40 mg on Day 1 of each 21-day cycle
Eligibility criteria:
Inclusion Criteria

Participant must have a histologically-confirmed metastatic or locally advanced solid tumor that has failed to respond to standard therapy, progressed despite standard therapy, or for which standard therapy does not exist.
Participant must have Performance Status 0 or 1.
Participant must have adequate organ function.

Exclusion Criteria

Participant has had chemotherapy, radiotherapy, or biological therapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to registration.
Participant has received 4 or greater regimens of chemotherapy (adjuvant therapy and incomplete 1 cycle treatment are not considered as 1 regimen).
Participant has known hypersensitivity to the components of study drug or its analogs.
Participant has had prescription or non-prescription drugs or other products known to be moderate or potent inhibitors/inducers of cytochrome P (CYP)3A4, or substrates of CYP3A4 with narrow therapeutic window.